Clinical trial
A Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 Ophthalmic Solution in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model for the Treatment of Dry Eye
NCT01960010 is registered in ClinicalTrials.gov with Mimetogen Pharmaceuticals USA, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 Ophthalmic Solution in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model for the Treatment of Dry Eye
- Lead sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2013
- Completion date
- August 31, 2014
- Enrollment
- 403 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.